Results · Apr-Jun 2026 · filed 13 Aug 2026
3B BlackBio Dx Q1 FY27 results
Sales grew 51% to ₹33.5 crore from ₹22.2 crore in Apr-Jun 2025.
Operating profit fell 28% to ₹8.5 crore, an operating margin of 25.4% (down 27.8 points from a year ago).
Net profit fell 29% to ₹9 crore from ₹12.6 crore in Apr-Jun 2025.
Against Jan-Mar 2026: sales −5%, net profit −8%.
Apr-Jun 2026 vs a year ago
| ₹ crore | Apr-Jun 2026 | Apr-Jun 2025 | Change |
|---|---|---|---|
| Sales | 33.5 | 22.2 | +51% |
| Operating profit (EBITDA) | 8.5 | 11.8 | −28% |
| Operating margin | 25.4% | 53.2% | −27.8 pts |
| Net profit | 9.0 | 12.6 | −29% |
Consolidated figures. Margins & ratios change in percentage points (pts).
The last 7 quarters
Filings that week
- 14 Aug 2026Announcement under Regulation 30 (LODR)-Newspaper Publication
- 13 Aug 2026Announcement under Regulation 30 (LODR)-Investor Presentation
- 13 Aug 2026Unaudited Financial Results For The Quarter Ended 30Th June, 2026
- 13 Aug 2026Board Meeting Outcome for Outcome Of Board Meeting
From the company's results filed on BSE (Consolidated). Business numbers only. Education & analysis, not investment advice or a recommendation.